As an important medical progress, chimeric antigen receptor T cell (CAR‐T) therapy targeting CD19 has shown great potential for patients with relapsed/refractory (R/R) B‐cell lymphoma.13, 14, 15, 16. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.